ISC 2024 | Biomarker exploration for advancing CADASIL therapeutics

Elisa Ferrante, PhD, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, sheds light on the continuous endeavors to investigate biomarkers for CADASIL, a rare, inherited form of vascular disease. Emphasizing the need to consolidate data, Dr Ferrante highlights how researcher collaboration is pivotal in facilitating more robust discoveries within the biomarker domain. The progress in genomics and proteomics has significantly improved this exploration, offering researchers the chance to pinpoint biomarkers for CADASIL. Several studies are underway that use large-scale omics assays, aimed at revealing distinctions in circulating proteins between CADASIL patients and controls. This interview took place during the International Stroke Conference 2024 in Phoenix, AZ.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.